MNCs for Bone Marrow Failure After Malignant Diseases Children Chemotherapy

• Status: Recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This project aims to investigate the therapeutic and repair effects of cord blood mononuclear cells (MNCs) on bone marrow failure after chemotherapy in children with malignant diseases. It is planned to collect 20 malignant children with bone marrow failure after chemotherapy and randomly divide them into two groups. The umbilical cord blood mononuclear cells were injected, ≥1×10^8 per infusion, once a week, and the recovery time of peripheral blood leukocytes, neutrophils, platelets and hemoglobin was observed. According to the recovery of myelosuppression, stop when the peripheral blood reaches leukocytes>1×10^9/L, neutrophils>0.5×10^9/L, platelets>25×10^9/L, and hemoglobin>60g/L at the same time. Use, share 1-4 times.

Statistical software was used to compare the changes of peripheral blood leukocytes, neutrophils, platelets and hemoglobin before the start of the test (0d) and 1d, 3d, 5d, 7d, 10d, and 14d after the start of the test, as well as the severity of concurrent infections and antibiotic use Time, number of infusions of blood products.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qianfoshan Hospital
• Collaborator: Chinese Medical Association

Criteria

Inclusion Criteria:

1. Age ≤ 17 years old;

2. Treated in pediatric hematology department from September 2021 to September 2024, patients with bone marrow failure after transplantation;

3. Eastern Cooperative Oncology Group(ECOG) score ≤ 2;

4. Sign the informed consent form (< 10 years old, signed by the guardian; ≥ 10 The children and their guardians signed the informed consent form before the selection.

Exclusion Criteria:

1. Those who have received thoracic radiotherapy in the past;

2. Those who do not meet the above inclusion criteria.